ALGN vs IONS
Align Technology vs Ionis Pharmaceuticals, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
| Metric | ALGN | IONS |
|---|
| AI Score |
73
|
43
|
| Price |
$172.86
|
$55.38
|
| P/E Ratio |
30.03×
|
-16.02×
|
| ROE |
10.1%
|
-77.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
98.2%
|
| Debt / Equity |
0.03×
|
5.50×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
46.6
|
| Beta |
1.653
|
0.4
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus IONS.
ALGN leads by 30 points.
ALGN scores 73/100 (Buy) versus IONS at 43/100 (Reduce).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value